Cannabinoid-1 Receptor Antagonist, Rimonabant, for Management of Obesity and Related Risks
نویسندگان
چکیده
منابع مشابه
Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks.
The prevalence of obesity has risen substantially during the past 25 years in the United States and most developed countries, with a related increase in type 2 diabetes mellitus.1,2 Almost one third of the adult US population is considered to be obese (body mass index [BMI] 30), and 1 in 20 is extremely obese (BMI 40).3 Nearly 17% of children and adolescents are overweight in the United States....
متن کاملBioactivation pathways of the cannabinoid receptor 1 antagonist rimonabant.
In the present work, the characterization of the biotransformation and bioactivation pathways of the cannabinoid receptor 1 antagonist rimonabant (Acomplia) is described. Rimonabant was approved in Europe in 2006 for the treatment of obesity but was withdrawn in 2008 because of a significant drug-related risk of serious psychiatric disorders. The aim of the present work is to characterize the b...
متن کاملRimonabant (Acomplia): The First Cannabinoid-1 Receptor Blocker for Obesity
INTRODUCTION The prevalence of obesity continues to rise. Current data indicate that the combined prevalence of overweight and obesity in adults in the U.S. is 66.3%. The prevalence for obesity alone in adults is 32.2%; for extreme obesity in adults, this figure is 4.8%. Approximately 17.1% of children and adolescents in the U.S. are overweight. Overweight is defined as a body mass index (BMI) ...
متن کاملInteraction between Antagonist of Cannabinoid Receptor and Antagonist of Adrenergic Receptor on Anxiety in Male Rat
Introduction: Anxiety is among the most common and treatable mental disorders. Adrenergic and cannabinoid systems have an important role in the neurobiology of anxiety. The elevated plus-maze (EPM) has broadly been used to investigate anxiolytic and anxiogenic compounds. The present study investigated the effects of intraperitoneal (IP) injection of cannabinoid CB1 receptor antagonist (AM251) i...
متن کاملCannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.
BACKGROUND Rimonabant is a selective type 1 cannabinoid (CB1) receptor antagonist. It may assist with smoking cessation by restoring the balance of the endocannabinoid system, which can be disrupted by prolonged use of nicotine. Rimonabant also seeks to address many smokers' reluctance to persist with a quit attempt because of concerns about weight gain. OBJECTIVES To determine whether select...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation
سال: 2006
ISSN: 0009-7322,1524-4539
DOI: 10.1161/circulationaha.105.596130